125 related articles for article (PubMed ID: 4028459)
1. Comparison of the clinical activity of mesulergine and pergolide in the treatment of hyperprolactinaemia.
Grossman A; Bouloux PM; Loneragan R; Rees LH; Wass JA; Besser GM
Clin Endocrinol (Oxf); 1985 May; 22(5):611-6. PubMed ID: 4028459
[TBL] [Abstract][Full Text] [Related]
2. Effectiveness of pergolide mesylate in long term treatment of hyperprolactinaemia.
Franks S; Horrocks PM; Lynch SS; Butt WR; London DR
Br Med J (Clin Res Ed); 1983 Apr; 286(6372):1177-9. PubMed ID: 6404378
[TBL] [Abstract][Full Text] [Related]
3. Mechanism of action and tolerance of mesulergine.
Lamberts SW; Klÿn JG; Oosterom R
Clin Pharmacol Ther; 1984 Nov; 36(5):620-7. PubMed ID: 6488683
[TBL] [Abstract][Full Text] [Related]
4. The long-acting dopamine agonist pergolide mesylate for treatment of hyperprolactinaemia.
Bergh T; Nillius SJ; Wide L
Acta Eur Fertil; 1984; 15(6):421-4. PubMed ID: 6536135
[TBL] [Abstract][Full Text] [Related]
5. The effect of dopamine agonist therapy on large functionless pituitary tumours.
Grossman A; Ross R; Charlesworth M; Adams CB; Wass JA; Doniach I; Besser GM
Clin Endocrinol (Oxf); 1985 May; 22(5):679-86. PubMed ID: 4028461
[TBL] [Abstract][Full Text] [Related]
6. Diagnosis and drug therapy of prolactinoma.
Ciccarelli E; Camanni F
Drugs; 1996 Jun; 51(6):954-65. PubMed ID: 8736617
[TBL] [Abstract][Full Text] [Related]
7. Treatment of hyperprolactinaemic patients with pergolide.
L'Hermite M; Debusschere PM; Gillet C; Deschepper C
Acta Endocrinol (Copenh); 1983 Aug; 103(4):441-5. PubMed ID: 6412498
[TBL] [Abstract][Full Text] [Related]
8. Rapid regression of pituitary tumours during bromocriptine treatment of women with hyperprolactinaemia.
Bergh T; Nillius SJ; Lundberg PO; Moström U; Enoksson P; Ohman L; Wide L
Ups J Med Sci; 1982; 87(3):259-67. PubMed ID: 7157557
[TBL] [Abstract][Full Text] [Related]
9. Treatment of hyperprolactinaemia with pergolide mesylate: acute effects and preliminary evaluation of long-term treatment.
Franks S; Horrocks PM; Lynch SS; Butt WR; London DR
Lancet; 1981 Sep; 2(8248):659-61. PubMed ID: 6116045
[TBL] [Abstract][Full Text] [Related]
10. Discordant responses of prolactinoma to two different dopamine agonists.
Ahmed SR; Shalet SM
Clin Endocrinol (Oxf); 1986 Apr; 24(4):421-6. PubMed ID: 3742834
[TBL] [Abstract][Full Text] [Related]
11. Effect of bromocriptine and pergolide on pituitary tumor size and serum prolactin.
Horowitz BL; Hamilton DJ; Sommers CJ; Bryan RN; Boyd AE
AJNR Am J Neuroradiol; 1983; 4(3):415-7. PubMed ID: 6410759
[TBL] [Abstract][Full Text] [Related]
12. Serum prolactin and ovarian function after discontinuation of drug treatment for hyperprolactinaemia: a study with bromocriptine and metergoline.
Mattei AM; Ferrari C; Ragni G; Benco R; Picciotti MC; Rampini P; Caldara R; Crosignani PG
Br J Obstet Gynaecol; 1984 Mar; 91(3):244-50. PubMed ID: 6704349
[TBL] [Abstract][Full Text] [Related]
13. Reduction in size of prolactin-secreting tumours in men treated with pergolide.
Kendall-Taylor P; Hall K; Johnston DG; Prescott RW
Br Med J (Clin Res Ed); 1982 Aug; 285(6340):465-7. PubMed ID: 6809126
[TBL] [Abstract][Full Text] [Related]
14. Pergolide for the treatment of pituitary tumors secreting prolactin or growth hormone.
Kleinberg DL; Boyd AE; Wardlaw S; Frantz AG; George A; Bryan N; Hilal S; Greising J; Hamilton D; Seltzer T; Sommers CJ
N Engl J Med; 1983 Sep; 309(12):704-9. PubMed ID: 6888442
[TBL] [Abstract][Full Text] [Related]
15. Comparison of dopamine agonists in the treatment of hyperprolactinemic syndromes: a multicenter study.
Blackwell RE; Bradley EL; Kline LB; Duvall ER; Vitek JJ; DeVane GW; Chang RJ
Fertil Steril; 1983 Jun; 39(6):744-8. PubMed ID: 6343127
[TBL] [Abstract][Full Text] [Related]
16. Effect of dopamine agonist withdrawal after long-term therapy in prolactinomas. Studies with high-definition computerised tomography.
Johnston DG; Hall K; Kendall-Taylor P; Patrick D; Watson M; Cook DB
Lancet; 1984 Jul; 2(8396):187-92. PubMed ID: 6146751
[TBL] [Abstract][Full Text] [Related]
17. Metergoline and bromocriptine in the management of tumoral and idiopathic hyperprolactinemia.
Falsetti L; Roggia A; Loda G; Turla R; Scagliola T; Schimberni M; Pontiroli AE
Horm Metab Res; 1983 Aug; 15(8):380-4. PubMed ID: 6618428
[TBL] [Abstract][Full Text] [Related]
18. The effect of quinagolide and cabergoline, two selective dopamine receptor type 2 agonists, in the treatment of prolactinomas.
Di Sarno A; Landi ML; Marzullo P; Di Somma C; Pivonello R; Cerbone G; Lombardi G; Colao A
Clin Endocrinol (Oxf); 2000 Jul; 53(1):53-60. PubMed ID: 10931080
[TBL] [Abstract][Full Text] [Related]
19. Cabergoline. A review of its pharmacological properties and therapeutic potential in the treatment of hyperprolactinaemia and inhibition of lactation.
Rains CP; Bryson HM; Fitton A
Drugs; 1995 Feb; 49(2):255-79. PubMed ID: 7729332
[TBL] [Abstract][Full Text] [Related]
20. Effect of mesulergine on prolactin secretion and dopamine D2 receptors-adaptive changes in diethylstilbestrol-induced hyperplasia of the rat anterior pituitary.
Pisarek H; Stepien H; Pawlikowski M
Endocr Regul; 1992 Mar; 26(1):17-22. PubMed ID: 1421203
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
